Progressive Medical Research

1. Eisai Inc. $4,908,558 102 payments
2. AstraZeneca Pharmaceuticals LP $1,922,616 20 payments
3. Biogen, Inc. $1,591,318 7 payments
4. AstraZeneca UK Limited $1,184,684 8 payments
5. Amgen Inc. $934,438 3 payments
6. Pfizer Inc. $884,468 82 payments
7. Novartis Pharmaceuticals Corporation $586,337 21 payments
8. E.R. Squibb & Sons, L.L.C. $490,545 13 payments
9. Genentech, Inc. $317,500 9 payments
10. Applied Therapeutics, inc. $254,762 46 payments

1. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $4,883,104 79 payments
2. Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $1,384,770 3 payments
3. A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension $697,707 3 payments
4. A Phase I randomized single-blind placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of AZD7503 following multiple ascending dose administration to patients with suspected non-cirrhotic non-alcoholic steatohepatitis (NASH) $613,480 3 payments
5. Ph2 Obesity $596,661 2 payments
6. A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele $552,867 3 payments
7. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $519,006 18 payments
8. A Phase I Randomized, Single blind, Placebo controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Multiple Ascending Subcutaneous Dose Administration in Subjects with Diabetes Type 2 $358,993 3 payments
9. P2 Obesity $337,777 1 payment
10. Prevention Study $315,000 8 payments

1. Other $240,377 22 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.